Dallah Healthcare Reports SAR 84.52M Net Profit in Three Months 2026
DALLAH HEALTH 4004.SA | 0.00 |
On 2026-05-10 08:58:32 (Saudi Time), Dallah Healthcare Co. announced its Interim financial results for the three months ended on March 31, 2026.
| Element List | Current Quarter | Similar quarter for previous year | %Change | Previous Quarter | % Change |
|---|---|---|---|---|---|
| Sales/Revenue | 1,013.26 | 832.75 | 21.676 | 1,110.44 | -8.751 |
| Gross Profit (Loss) | 334.08 | 297.61 | 12.254 | 398.23 | -16.108 |
| Operational Profit (Loss) | 120.36 | 177.89 | -32.34 | 154.95 | -22.323 |
| Net Profit (Loss) Attributable to Shareholders of the Issuer | 84.52 | 155.56 | -45.667 | 116.54 | -27.475 |
| Total Comprehensive Income Attributable to Shareholders of the Issuer | 84.58 | 155.49 | -45.604 | 111.94 | -24.441 |
| All figures are in (Millions) Saudi Arabia, Riyals | |||||
| Element List | Current Period | Similar period for previous year | %Change |
|---|---|---|---|
| Total Shareholders Equity (after Deducting Minority Equity) | 4,100.87 | 4,060.93 | 0.983 |
| Profit (Loss) per Share | 0.84 | 1.59 | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
Year-on-Year Performance Drivers
Sales increased 21.676% YoY to SAR 1,013.26 million, driven by a 27.5% rise in patient visits across facilities, particularly at Dallah Al-Khobar Hospital and Dallah Al-Ahsa Hospital following acquisitions. Net profit declined 45.667% YoY to SAR 84.52 million, primarily due to the absence of a SAR 51 million non-recurring real estate gain recorded in Q1 2025 and increased financing costs and operating expenses of SAR 64 million from consolidating the acquired hospitals' full quarterly results versus only 8 days in the prior year period.
Quarter-on-Quarter Performance Drivers
QoQ revenue declined 8.751% to SAR 1,013.26 million due to seasonal factors including Ramadan, Eid Al-Fitr holidays, and extended school breaks, resulting in a 15% drop in patient visits to 936 thousand. Net profit fell 27.475% to SAR 84.52 million primarily driven by the SAR 64 million decrease in gross profit from lower revenues, though the company reduced operating and financing costs by SAR 44 million to partially offset the impact.
Other Items
The external auditor issued an unmodified conclusion with no additional comments, disclaimers, or adverse opinions noted. No material risks or going concern issues were identified in the interim financial results. Total shareholders equity increased 0.983% to SAR 4,100.87 million compared to the prior year period. Earnings per share decreased to SAR 0.84 from SAR 1.59 in the comparable quarter. The company maintained EBITDA growth of 7% to SAR 194 million when adjusted for the prior year's non-recurring gain, demonstrating operational resilience despite seasonal headwinds.
Original announcement:
https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anId=95159&anCat=1&cs=4004&locale=arAttached PDF document link:
https://www.saudiexchange.sa/Resources/fsPdf/21212_435_2026-05-10_08-30-35_en.pdfImportant Notice: The announcement information and market data in this report are sourced directly from the Saudi Exchange (Tadawul). This summary is generated by Sahm’s proprietary AI model for informational purposes only. While we strive for accuracy, it should not be construed as financial advice or an investment recommendation.